Physician profile
Jeanelle King
NPI 1316966997
$424,130.57
in general payments reported to CMS, 2019-2025
24 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $61K · 2023: $127K · 2024: $110K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $184K · Travel and Lodging: $122K · Food and Beverage: $18K · Consulting Fee: $14K · Honoraria: $5,079 · Education: $41.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $184,034.07 |
| Travel and Lodging | $121,899.92 |
| Food and Beverage | $18,191.41 |
| Consulting Fee | $14,023.06 |
| Honoraria | $5,078.75 |
| Education | $41.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $263,349.94 | 2021-2025 | Libtayo |
| Pfizer INC. | $61,694.19 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $50,190.03 | 2022-2025 | Opdivo, Augtyro, Opdualag |
| Genzyme Corporation | $21,883.00 | 2021-2022 | |
| Array Biopharma INC | $10,717.05 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Immunocore Limited | $9,592.51 | 2023-2025 | Kimmtrak |
| Pharmacosmos Therapeutics INC. | $2,906.53 | 2024 | Monoferric |
| Merck Sharp & Dohme LLC | $2,807.69 | 2022-2025 | Keytruda, Welireg |
| Novartis Pharma Ag | $507.00 | 2021 | |
| Janssen Biotech, INC. | $75.55 | 2023-2024 | Rybrevant, Akeega, Erleada |
| Daiichi Sankyo INC. | $70.85 | 2022-2024 | Enhertu |
| Seagen INC. | $41.99 | 2024 | |
| Servier Pharmaceuticals LLC | $36.23 | 2025 | |
| Abbvie INC. | $33.86 | 2025 | |
| Eisai INC. | $25.25 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $25.09 | 2024 | |
| Kite Pharma, INC. | $24.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.76 | 2022 | |
| Genentech USA, INC. | $23.50 | 2023 | Lunsumio |
| Caris Mpi, INC. | $23.10 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $21.34 | 2024 | Alunbrig |
| Tempus Ai, INC | $19.99 | 2024 | Xt Cdx |
| Emd Serono, INC. | $19.41 | 2023 | Bavencio |
| Astrazeneca Pharmaceuticals Lp | $17.89 | 2024 | Calquence |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanelle King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.